All In Biotech

Investigational drug · Phase 3

HS-10382

Also called: MK-4208, Tern-701

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Myeloid Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

7

Any phase or sponsor naming "HS-10382"

First trial start

2024

Mar 26, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HS-10382", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Myeloid Leukemia
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Chronic Myeloid Leukemia, Chronic Phase

Approved drugs for the same conditions: Chronic myeloid leukemia · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "HS-10382" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 7 on PubMed

Also in development for Chronic Myeloid Leukemia

  • OlverembatinibPhase 34 trials

    Ascentage Pharma Group Inc. · Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed/Refractory Acute Myeloid Leukaemia

  • TGRX-678Phase 32 trials

    Shenzhen TargetRx Co., Ltd. · Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myeloid Leukemia

  • FlumatinibPhase 31 trial

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Chronic Myeloid Leukemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.